New insights into p53 protein stabilisation in oral squamous cell carcinoma

Oral Oncology

Volumn 35, Issue 1, 1999, Pages 45-55

  Partridge, M ^a   Kiguwa, S ^a   Emilion, G ^a   Pateromichelakis, S ^a   A'Hern, R ^b   Langdon, J D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chromosome deletions; Gene; Loss of heterozygosity; Microsatellite markers; Mouth neoplasms; Oral cancer; p53; Suppressor; Tumour

Indexed keywords

PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MOUTH CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BLOTTING, NORTHERN; CARCINOMA, SQUAMOUS CELL; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032890030     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(98)00051-7     Document Type: Article

References (64)

1. Chang F., Syrjanen S., Syrjanen K. Implications of the p53 tumour suppressor gene in clinical oncology. Journal of Clinical Oncology. 13:1995;1009-1022.
2. Langdon J. D., Partridge M. Expression of the tumour suppressor gene p53 in oral cancer. British Journal of Oral and Maxillofacial Surgery. 30:1992;214-220.
3. Warnakulasuriya K. A. A. S., Johnson N. W. Expression of p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions. Journal of Oral Pathology and Medicine. 21:1992;404-408.
4. Watling D. L., Gown A. M., Coltrera M. D. Over-expression of p53 in head and neck cancer. Head and Neck. 14:1992;437-444.
5. Ogden G. R., Kiddie R. A., Lunny D. P., Lane D. P. Assessment of p53 protein expression in normal, benign and malignant oral mucosa. Journal of Pathology. 166:1992;389-394.
6. Field J. K., Spandidos D. A., Malliri A., Yiagnisis M., Gosney J. R., Stell P. M. Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. British Journal of Cancer. 64:1991;573-577.
7. El-Naggar A. D., Lai S., Luna M. A., Zhou X-D., Weber R. S., Goepfert H., Batsakis J. G. Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. International Journal of Cancer. 64:1995;196-201.
8. Ahomadegbe J. C., Barrois M., Fogel S., et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumours and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene. 10:1995;1217-1227.
9. Boyle J. O., Hakim J., Koch W., et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Research. 53:1993;4477-4480.
10. Brennan J. A., Boyle J. O., Koch W. M., et al. Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. New England Journal of Medicine. 332:1995;712-717.
11. Brachman D. G., Graves D., Vokes E., et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Research. 52:1992;4832-4836.
12. Nylander K., Nilsson P., Mehle C., Roos G. p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. British Journal of Cancer. 71:1995;826-830.
13. Harris C. C., Hollstein M. Clinical implications of the p53 tumour-suppressor gene. New England Journal of Medicine. 329:1993;1318-1327.
14. Deng G., Chen L-C., Schott D. R., et al. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Research. 54:1994;499-505.
15. Thompson A. M. p53 allele losses, mutation and expression in breast cancer and their relationship to clinicopathological parameters. International Journal of Cancer. 50:1992;528-532.
16. Brooks J. D., Bova G. S., Ewing C. M., et al. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Research. 56:1996;3814-3822.
17. Li Y-Q., Pavelic Z. P., Wang L. J., et al. Altered p53 in microdissected, metachronous, premalignant and malignant oral lesions from the same patients. Journal of Clinical Pathology: Molecular Pathology. 48:1995;M269-M272.
18. Wagata T., Shibagaki I., Imamura M., et al. Loss of 17p, mutation of the p53 gene and overexpression of p53 protein in oesophageal squamous cell carcinomas. Cancer Research. 53:1993;846-850.
19. Brachmann R. K., Vidal M., Boeke J. D. Dominant-negative mutations in yeast hit cancer hot spots. Proceedings of the National Academy of Sciences, USA. 93:1996;4091-4095.
20. Kemp C. J., Donehower L. A., Bradley A., Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumours. Cell. 74:1993;813-822.
21. Varley J. M., Brammar W. J., Lane D. P., Swallow J. E., Dolan C., Walker R. A. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene. 6:1991;413-421.
22. Dunn J. M., Hastrich D. J., Newcomb P., Webb J. C. J., Maitland N. J., Farndon J. R. Correlation between p53 mutations and antibody staining in breast carcinoma. British Journal of Surgery. 80:1993;1410-1412.
23. Macgeoch C., Barnes D. M., Newton J. A., et al. p53 protein detected by immunohistochemical staining is not always mutant. Disease Markers. 11:1993;239-250.
24. Helland A., Holm R., Kristensen G., et al. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. Journal of Pathology. 171:1993;105-114.
25. Riou G., Barrois M., Prost S., Terrier M. J., Theodore C., Levine A. J. The p53 and mdm-2 genes in human testicular germ cell tumours. Molecular Carcinogenesis. 12:1995;124-131.
26. Tominaga O., Hamelin R., Trouvat V., Salmon R. J., Lesec G., Thomas G., Remvikos Y. Frequently elevated content of immunochemically defined wild-type p53 protein in colorectal adenomas. Oncogene. 8:1993;2653-2658.
27. Cripps K. J., Purdie C. A., Carder P. J., White S., Komine K., Bird C. C., Wyllie A. H. A study of p53 protein versus point mutation in colorectal carcinoma. Oncogene. 9:1994;2739-2743.
28. Dix B., Robbins P., Carrello S., House A., Lacopetta B. Comparison of p53 gene mutation and protein expression in colorectal carcinoma. British Journal of Cancer. 70:1994;585-590.
29. Xu L., Chen Y-T., Huvos A. G., et al. Over-expression of p53 protein in squamous cell carcinoma of head and neck without apparent gene mutations. Diagnostic Molecular Pathology. 3:1994;83-92.
30. Lane D. P. The regulation of p53 function: Steiner Award Lecture. International Journal of Cancer. 57:1994;623-627.
31. Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry? Journal of Pathology. 166:1992;329-330.
32. Hall P. A., McKee P. H., Menage H. D., Dover R., Lane D. P. High levels of p53 protein in UV irradiated human skin. Oncogene. 8:1993;203-207.
33. Carbone D. P., Mitsudomi T., Chiba I., et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. Chest. 106:1994;377S-381S.
34. Midgeley C. A., Lane D. P. p53 protein stability in tumour cells is not determined by mutation but is dependent on mdm2 binding. Oncogene. 15:1997;1179-1189.
35. Lin J., Teresky A. K., Levine A. J. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene. 10:1995;2387-2390.
36. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
37. Kubbutat M. H. G., Jones S. N., Vousden K. Regulation of p53 stability by mdm2. Nature. 387:1997;299-303.
38. Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83.
39. Wu X., Bayle J. H., Olson D., Levine A. J. The p53-mdm2 autoregulatory feedback loop. Genes and Development. 7:1993;1126-1132.
40. Lane, D.P., Hall, P.A. MDM2-arbiter of p53's destruction. Trends in Biological Sciences 1997; 372-74.
41. Younes F., Quartey E. L., Kiguwa S., Partridge M. Expression of TNF and the 55kDa TNF receptor in epidermis, oral mucosa, lichen planus and squamous cell carcinoma. Oral Diseases. 2:1996;25-31.
42. Partridge M., Emilion G., Langdon J. D. LOH at 3p correlates with a poor survival in oral squamous cell carcinoma. British Journal of Cancer. 73:1996;366-371.
43. Vogelstein B., Fearnon E. R., Kern S. E., et al. Allelotype of colorectal carcinoma. Science. 244:1989;207-214.
44. Gusterson B. A., Ramaswamy R., Warren W., et al. Expression of p53 in premalignant and malignant squamous epithelia. Oncogene. 6:1991;1785-1789.
45. Mitsudomi T., Steinberg S. M., Oie H. K., et al. p53 mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 7:1992;171-180.
46. Auffrey C., Rougeon F. Purification of mouse immunoglobulin heavy chain mRNA from total myeloma tumour RNA. European Journal of Biochemistry. 107:1980;303-314.
47. Partridge M., Green M. R., Langdon J. D., Feldmann M. Production of TGFα and TGFβ by cultured keratinocytes, skin and oral squamous cell carcinoma-potential autocrine regulation of normal and malignant epithelial cell proliferation. British Journal of Cancer. 60:1989;542-548.
48. Matlashewski G. J., Tuck S., Pim D., Lamb P., Schneider J., Crawford L. V. Primary structure polymorphism at amino acid residue 72 of human p53. Molecular Cell Biology. 7:1987;961-963.
49. Cleveland D. W., MacDonald R. J., Cowan N. J., Rutter W. J., Kirschner M. W. Number and evolutionary conservation of α and β tubulin and cytoplasmic β and γ actin genes using specific cloned cDNA probes. Cell. 20:1980;95-105.
50. Adamson R., Jones A. S., Field J. K. Loss of heterozygosity studies on chromosome 17 in head and neck cancer using microsatellite markers. Oncogene. 9:1994;2077-2082.
51. Largey J. S., Meltzer S. J., Yin J., Norris K., Sauk J. J., Archibald D. W. Loss of heterozygosity of p53 in oral cancers demonstrated by the polymerase chain reaction. Cancer. 71:1993;1933-1937.
52. Wales M. M., Biel M. A., Diery W. E., et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Medicine. 1:1995;570-577.
53. Martinec D., Whitlock J. A. Improved detection of p53 point mutations by dideoxyfingerprinting (ddF). Oncogene. 13:1996;2039-2044.
54. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumour suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Research. 54:1994;4855-4878.
55. Min B-M., Baek J-H., Shin K-H., Gujuluva C. N., Cherrick H. M., Park N-H. Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines. Oral Oncology, European Journal of Cancer. 30B:(5):1994;338-345.
56. Riethdorf S., Friedrich R. E., Ostwald C., et al. p53 gene mutation and HPV and neck squamous cell carcinomas do not correlate with overall survival: a long term follow-up study. Journal of Oral Pathology and Medicine. 26:1997;315-321.
57. Maestro R., Dolcetti R., Gasparotto D., et al. High frequency of p53 gene alterations associated with protein over-expression in human squamous cell carcinoma of the larynx. Oncogene. 7:1992;1159-1166.
58. Dazard J-E., Augias D., Neel H., et al. MDM2 protein is expressed in different layers of normal human skin. Oncogene. 14:1997;1123-1128.
59. Price B. D., Park S. J. DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Research. 54:1994;896-899.
60. Sarhanis P., Redmen C., Perrett C., et al. Epithelial ovarian cancer: influence of polymorphism to the glutathione S-transferase GSTM1 and GST1 loci on p53 expression. British Journal of Cancer. 74:1996;1757-1761.
61. Birchall M. A., Winterford C. M., Allan D. J., Harmon B. V. Apoptosis in normal epithelium, premalignant and malignant lesions of the oropharynx and oral cavity: a preliminary study. Oral Oncology European Journal of Cancer. 31B:(6):1995;380-383.
62. Liloglou T., Scholes A. G. M., Spandidos D. A., et al. p53 mutations in squamous cell carcinoma of the head and neck predominate in a subgroup of former and present smokers with a low frequency of genetic instability. Cancer Research. 57:1997;4070-4074.
63. Kaghad M., Bonnet H., Yang A., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:1997;809-819.
64. Schmale H., Bamburger C. A novel protein with strong homology to the tumour suppressor p53. Oncogene. 15:1997;1363-1367.